All Web Images Videos News
Settings
Appearance
Site Icons
Font Size
Font
General
Infinite Scroll
Open Links in a New Tab
Safe Search
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Business Wire - Feb 18, 2025
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
PMLiVE - Feb 18, 2025
Galderma doubles up on Nemluvio approvals
The Pharma Letter - Feb 18, 2025
UK latest to back Galderma's antibody for skin conditions
FirstWord Pharma - Feb 18, 2025
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Pharmaceutical Technology - Feb 14, 2025
Galderma Wins Swiss Approval for Prurigo Nodularis, Atopic Dermatitis Treatment -February 18, 2025 at 03:16 am EST
MarketScreener - Feb 18, 2025
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Yahoo Finance - Feb 14, 2025
Swiss Stocks Begin Week Upbeat; Galderma Gains on UK Win
TradingView - Feb 17, 2025
Galderma’s Innovations in Regenerative Aesthetics: Insights from Gerry Muhle
Dermatology Times - Jan 31, 2025
Galderma Unveils a New Wrinkle Relaxer That Works in a Day
NewBeauty - Jan 31, 2025
More results